Info

SLIL is a world leader in the field of polyamine analog research and is developing new therapies for cancer and other diseases. SLIL also has an exclusive license to the Sequential Pathogenesis technology and has the opportunity to develop therapeutic and diagnostic breakthroughs in cancer and other diseases. The Company's mission is to fully realize these opportunities.